Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (5134)	12/17/1997 8:22:00 PM
From: Maxer	Respond to of 17367

Somehow, we gotta crank up the publicity machine. Let the world know about XOMA. Granted, this is a tough time with the market so uncertian, but start now, the market will be receptive by the time the material is ready. Somehow, XOMA has to say: we got this, and this, and this is in phaise III, etc. I'm totally of the belief you aren't discovered unless you make yourself discoverable. Web sites and publicity releases are cheep, fast, and can be effective. Use 'em.

To: aknahow who wrote (5134)	12/17/1997 8:57:00 PM
From: Robert K.	Respond to of 17367

George good investigative work. Thanks. BTW IMO new patents arnt "that" important. BPI patents excite me though. Max, they will toot their horn when its really worth tooting. Also I thought T&A stood for something more important ;-) -well to me anyways.

To: aknahow who wrote (5134)	12/18/1997 8:45:00 AM
From: Robert K.	Read Replies (2) \| Respond to of 17367

At least 2 presentations. Some heavy hitters there. This presentation and wording peaks my interest even more...... .2:45 Antifungal Peptides Derived from Bactericidal/Permeability-Increasing Protein: Preclinical Research Summary Roger G. Little, PhD, Director, Biochemistry Department, XOMA Corporation While elucidating BPI's structure and function, we have discovered that peptides from a particular region (amino acids 142-169) within BPI had unexpectedly potent activity against Candida albicans. Utilizing an iterative synthesis/screening process, the initial activity has been amplified into a series of peptides characterized by: fungicidal activity against a broad range of fungal genera in vivo antifungal activity in mortality and target organ CFU analysis fungicidal activity against polyene- and azole-resistant Candida albicans Currently, lead compounds have been prioritized based on in vivo efficacy in murine systemic candidiasis and aspergillosis models and on in vitro fungicidal activity. (nothing we dont know but..............)